Review

human ovarian cancer cell line skov3 (ATCC)

ATCC is a verified supplier

ATCC manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

ATCC human ovarian cancer cell line skov3

Specific IFN-γ and TNF-α release of T lymphocytes transduced with TIM-3-silenced HER2-specific chimeric antigen receptor (CAR) or HER2-specific CAR. (A, B) TIM-3-silenced CAR-T cells and control T cells were co-incubated with Galectin-9 + or Galectin-9 – <t>SKOV3</t> tumor cells (E:T ratio 5:1 or 10:1). At 20 h after coculture, a specific enzyme-linked immunosorbent assay was used to analyze the supernatant for IFN-γ cytokine-release. Results were presented as mean ± standard deviation. (C, D) The detection of TNF-α in the same culture supernatant. Results were presented as mean ± standard deviation. ∗ P < 0.05 and ∗∗ P < 0.01.

Human Ovarian Cancer Cell Line Skov3, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 7638 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+ovarian+cancer+cell+line+skov3/SK-OV-3/pmc13084341-20-13-22
Average 99 stars, based on 7638 article reviews

human ovarian cancer cell line skov3 - by Bioz Stars, 2026-09

99/100 stars

Images

1) Product Images from "Blockade of co-inhibitory receptor immune checkpoint protein TIM3/CD366 augments the anti-cancer activity of CAR-T therapy in solid tumors: An ovarian cancer example"

Article Title: Blockade of co-inhibitory receptor immune checkpoint protein TIM3/CD366 augments the anti-cancer activity of CAR-T therapy in solid tumors: An ovarian cancer example

Journal: Genes & Diseases

doi: 10.1016/j.gendis.2025.101978

Figure Legend Snippet: Specific IFN-γ and TNF-α release of T lymphocytes transduced with TIM-3-silenced HER2-specific chimeric antigen receptor (CAR) or HER2-specific CAR. (A, B) TIM-3-silenced CAR-T cells and control T cells were co-incubated with Galectin-9 + or Galectin-9 – SKOV3 tumor cells (E:T ratio 5:1 or 10:1). At 20 h after coculture, a specific enzyme-linked immunosorbent assay was used to analyze the supernatant for IFN-γ cytokine-release. Results were presented as mean ± standard deviation. (C, D) The detection of TNF-α in the same culture supernatant. Results were presented as mean ± standard deviation. ∗ P < 0.05 and ∗∗ P < 0.01.

Techniques Used: Transduction, Control, Incubation, Enzyme-linked Immunosorbent Assay, Standard Deviation

TIM-3 silencing augmented the anti-tumor activity of chimeric antigen receptor-T (CAR-T) cells in vivo . 2 × 10 6 SKOV3 tumor cells expressing luciferase were intraperitoneally inoculated in a xenograft mouse model, and 7 days after inoculation, the 2 × 10 6 HER2-specific CAR-T kdTim-3 cells or CAR-T cells, or untreated T cells were intraperitoneally administered. (A, B) Tumor growth was monitored using an in vivo imaging system. (C) Survival curve of 80-day post-treatment. ∗ P < 0.05 and ∗∗ P < 0.01.

Figure Legend Snippet: TIM-3 silencing augmented the anti-tumor activity of chimeric antigen receptor-T (CAR-T) cells in vivo . 2 × 10 6 SKOV3 tumor cells expressing luciferase were intraperitoneally inoculated in a xenograft mouse model, and 7 days after inoculation, the 2 × 10 6 HER2-specific CAR-T kdTim-3 cells or CAR-T cells, or untreated T cells were intraperitoneally administered. (A, B) Tumor growth was monitored using an in vivo imaging system. (C) Survival curve of 80-day post-treatment. ∗ P < 0.05 and ∗∗ P < 0.01.

Techniques Used: Activity Assay, In Vivo, Expressing, Luciferase, In Vivo Imaging

Cell Culture:

Article Title: Blockade of co-inhibitory receptor immune checkpoint protein TIM3/CD366 augments the anti-cancer activity of CAR-T therapy in solid tumors: An ovarian cancer example
Article Snippet: .. Human cervical cancer cell line HeLa, lentivirus packaging cell line HEK 293TD, and human ovarian cancer cell line SKOV3 were purchased from American Type Culture Collection (Manassas, Virginia, USA) and cultured in Dulbecco's modified Eagle's medium (Invitrogen, Grand Island, New York) supplemented with 10% heat-inactivated fetal bovine serum. .. Five different TIM-3 targeting shRNA sequences were purchased from Sigma, USA.

Article Title: Tumor Intrinsic METTL5 Modulates ATF4 Translation to Prevent T Cell‐Induced Ferroptosis in Ovarian Cancer
Article Snippet: The parental and genetically modified ID8 (#SCC145, Millipore‐Sigma, Burlington, MA) lines were cultured in Dulbecco's modified Eagle's medium (DMEM; #11965118, ThermoFisher Scientific, Waltham, MA) supplemented with 5% heat‐inactivated fetal bovine serum (FBS; # S11150 , R&D System, Minneapolis, MN), 5 μg mL −1 of insulin, transferrin and sodium selenite (1×ITS, #I3146, Millipore‐Sigma) and 100 μg mL −1 of Normocin (#ant‐nr‐1, InvivoGen, San Diego, CA). .. Human embryonic kidney (HEK) 293T and human ovarian cancer cell line SKOV3 were obtained from the American Type Culture Collection (#CRL‐3216 and #HTB‐77, ATCC, Bethesda, MD) and cultured in DMEM supplemented with 10% heat‐inactivated FBS and 100 μg mL −1 of Normocin. .. All cell lines with stable expression of gRNAs generated in this study were cultured under the treatment of 2 μg/ml of puromycin (#A1113803, Gibco, Carlsbad, CA) with the culture media described above.

Modification:

other:

Article Title: Magnetically triggered thermoelectric heterojunctions with an efficient magnetic-thermo-electric energy cascade conversion for synergistic cancer therapy.
Article Snippet: The mouse colorectal cancer cell line CT26 (catalog number: CRL2638) and human ovarian cancer cell line SKOV3 (catalog number: HTB-77) were sourced from the American Type Culture Collection (ATCC).

Article Title: Tumor Intrinsic METTL5 Modulates ATF4 Translation to Prevent T Cell-Induced Ferroptosis in Ovarian Cancer.
Article Snippet: For gp100-specific T cells, splenocytes were isolated from Pmel mice and cultured in complete RPMI1640 media (10% FBS, 20 mm HEPES, 1 mm sodium pyruvate, 50 × 10−6 m 2- mercaptoethanol, 2 × 10−3 m l-glutamine and 100 μg mL−1 of Normocin) supplied with 500 IU mL−1 recombinant human interleukin-2 (rhIL-2; Prometheus Laboratories, NDC Code 65483-116-07, San Diego, CA) and 0.3 μg mL−1 anti-mouse CD3 (#555273, BD Biosciences, San Jose, CA) for 24 h. After stimulation, cells were maintained in the culture medium with 500 IU mL−1 IL-2 for at least 6 days.

Article Title: Magnetically triggered thermoelectric heterojunctions with an efficient magnetic-thermo-electric energy cascade conversion for synergistic cancer therapy
Article Snippet: The mouse colorectal cancer cell line CT26 (catalog number: CRL-2638) and human ovarian cancer cell line SKOV3 (catalog number: HTB-77) were sourced from the American Type Culture Collection (ATCC).

Article Title: Protocol to profile tumor and microenvironment from ovarian cancer patient samples and evaluate cell-based therapy using in vitro killing assays
Article Snippet: Human ovarian cancer cell line SKOV3 , ATCC , CATHTB-77, RRID: CVCL_0532.

Image Search Results

Journal: Genes & Diseases

Article Title: Blockade of co-inhibitory receptor immune checkpoint protein TIM3/CD366 augments the anti-cancer activity of CAR-T therapy in solid tumors: An ovarian cancer example

doi: 10.1016/j.gendis.2025.101978

Figure Lengend Snippet: Specific IFN-γ and TNF-α release of T lymphocytes transduced with TIM-3-silenced HER2-specific chimeric antigen receptor (CAR) or HER2-specific CAR. (A, B) TIM-3-silenced CAR-T cells and control T cells were co-incubated with Galectin-9 + or Galectin-9 – SKOV3 tumor cells (E:T ratio 5:1 or 10:1). At 20 h after coculture, a specific enzyme-linked immunosorbent assay was used to analyze the supernatant for IFN-γ cytokine-release. Results were presented as mean ± standard deviation. (C, D) The detection of TNF-α in the same culture supernatant. Results were presented as mean ± standard deviation. ∗ P < 0.05 and ∗∗ P < 0.01.

Article Snippet: Human cervical cancer cell line HeLa, lentivirus packaging cell line HEK 293TD, and human ovarian cancer cell line SKOV3 were purchased from American Type Culture Collection (Manassas, Virginia, USA) and cultured in Dulbecco's modified Eagle's medium (Invitrogen, Grand Island, New York) supplemented with 10% heat-inactivated fetal bovine serum.

Techniques: Transduction, Control, Incubation, Enzyme-linked Immunosorbent Assay, Standard Deviation

Journal: Genes & Diseases

Article Title: Blockade of co-inhibitory receptor immune checkpoint protein TIM3/CD366 augments the anti-cancer activity of CAR-T therapy in solid tumors: An ovarian cancer example

doi: 10.1016/j.gendis.2025.101978

Figure Lengend Snippet: TIM-3 silencing augmented the anti-tumor activity of chimeric antigen receptor-T (CAR-T) cells in vivo . 2 × 10 6 SKOV3 tumor cells expressing luciferase were intraperitoneally inoculated in a xenograft mouse model, and 7 days after inoculation, the 2 × 10 6 HER2-specific CAR-T kdTim-3 cells or CAR-T cells, or untreated T cells were intraperitoneally administered. (A, B) Tumor growth was monitored using an in vivo imaging system. (C) Survival curve of 80-day post-treatment. ∗ P < 0.05 and ∗∗ P < 0.01.

Techniques: Activity Assay, In Vivo, Expressing, Luciferase, In Vivo Imaging

A Volcano plot of GLUD1 expression in epithelial ovarian cancer (EOC) from GEO datasets. Colors indicate gene expression levels: red for high, blue for low, and gray for non-significant expression changes. B Venn diagram illustrating the overlap among DEGs, anoikis-related genes, and amino acid metabolism–related genes. C GLUD1 expression in the GSE27651 dataset. Gene expression levels are shown with red representing tumor tissues and blue representing normal controls. D Kaplan-Meier curves showing overall survival differences between high and low GLUD1 expression groups in EOC patients from the TCGA dataset. Red and blue lines represent high and low expression levels, respectively. E Western blot analysis of GLUD1 expression in OVCAR3 and SKOV3 cells cultured under detached conditions. GAPDH was used as a loading control. F Representative immunohistochemistry images (Upper) and quantification (Lower) of GLUD1 expression in para-tumor, primary, and metastatic EOC tissues. G Overall survival curve and disease-free survival curve for EOC patients with low or high expression of GLUD1 based on IHC staining index. Data are presented as mean ± SD. * p < 0.05, ** p < 0.01.

Journal: NPJ Precision Oncology

Article Title: GLUD1 supports ovarian cancer progression by counteracting anoikis via ARAF/MEK/ERK signaling

doi: 10.1038/s41698-026-01349-6

Figure Lengend Snippet: A Volcano plot of GLUD1 expression in epithelial ovarian cancer (EOC) from GEO datasets. Colors indicate gene expression levels: red for high, blue for low, and gray for non-significant expression changes. B Venn diagram illustrating the overlap among DEGs, anoikis-related genes, and amino acid metabolism–related genes. C GLUD1 expression in the GSE27651 dataset. Gene expression levels are shown with red representing tumor tissues and blue representing normal controls. D Kaplan-Meier curves showing overall survival differences between high and low GLUD1 expression groups in EOC patients from the TCGA dataset. Red and blue lines represent high and low expression levels, respectively. E Western blot analysis of GLUD1 expression in OVCAR3 and SKOV3 cells cultured under detached conditions. GAPDH was used as a loading control. F Representative immunohistochemistry images (Upper) and quantification (Lower) of GLUD1 expression in para-tumor, primary, and metastatic EOC tissues. G Overall survival curve and disease-free survival curve for EOC patients with low or high expression of GLUD1 based on IHC staining index. Data are presented as mean ± SD. * p < 0.05, ** p < 0.01.

Article Snippet: The human embryonic kidney cell line HEK293T and human ovarian cancer cell lines SKOV3, OVCAR3, HO8910PM, ES-2, A2780, and Caov-3 were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA).

Techniques: Expressing, Gene Expression, Western Blot, Cell Culture, Control, Immunohistochemistry

A Western blot analysis of GLUD1 expression in ovarian cancer cells with GLUD1 overexpression or knockdown. B Representative fluorescence images of live (green) and dead (red) cells under detached conditions (left) and quantification of live dead cell ratios (right). C Flow cytometric analysis of apoptosis in ovarian cancer cells cultured under detached conditions and corresponding quantification. D Transwell migration assays of SKOV3 and OVCAR3 cells with GLUD1 overexpression or knockdown and quantification of migrated cells. E Wound healing assays assessing migratory capacity of SKOV3 and OVCAR3 cells and quantification of wound closure. All experiments were performed in three independent biological replicates. Data are presented as mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001.

Journal: NPJ Precision Oncology

Article Title: GLUD1 supports ovarian cancer progression by counteracting anoikis via ARAF/MEK/ERK signaling

doi: 10.1038/s41698-026-01349-6

Figure Lengend Snippet: A Western blot analysis of GLUD1 expression in ovarian cancer cells with GLUD1 overexpression or knockdown. B Representative fluorescence images of live (green) and dead (red) cells under detached conditions (left) and quantification of live dead cell ratios (right). C Flow cytometric analysis of apoptosis in ovarian cancer cells cultured under detached conditions and corresponding quantification. D Transwell migration assays of SKOV3 and OVCAR3 cells with GLUD1 overexpression or knockdown and quantification of migrated cells. E Wound healing assays assessing migratory capacity of SKOV3 and OVCAR3 cells and quantification of wound closure. All experiments were performed in three independent biological replicates. Data are presented as mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001.

Techniques: Western Blot, Expressing, Over Expression, Knockdown, Fluorescence, Cell Culture, Migration

Review

human ovarian cancer cell line skov3 (ATCC)

Structured Review

Images

1) Product Images from "Blockade of co-inhibitory receptor immune checkpoint protein TIM3/CD366 augments the anti-cancer activity of CAR-T therapy in solid tumors: An ovarian cancer example"

Related Articles

Cell Culture:

Modification:

other:

Similar Products

Image Search Results